Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30 Suppl 2:B26–36.
Article
PubMed
Google Scholar
Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17.
Article
PubMed
PubMed Central
Google Scholar
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27 Suppl 2:B51–63.
Article
PubMed
Google Scholar
Memish ZA, Goubeaud A, Broker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J Infect Public Health. 2010;3(4):143–51.
Article
PubMed
Google Scholar
Goodman AL, Masuet-Aumatell C, Halbert J, Zuckerman JN. Awareness of meningococcal disease among travelers from the United Kingdom to the meningitis belt in Africa. Am J Trop Med Hyg. 2014;91(2):281–6.
Article
PubMed
PubMed Central
Google Scholar
Dijkstra JA, Chappuis F, Loutan L. Vaccine-preventable diseases in long-term expatriates. J Travel Med. 2005;12 Suppl 1:S47–57.
PubMed
Google Scholar
Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012;25(5):507–17.
Article
PubMed
Google Scholar
World Health Organization: Global Alert and Response (GAR). Meningococcal disease in the Philippines - update 2. 28 January 2005 Available at: http://www.who.int/csr/don/2005_01_28a/en/.
Lingappa JR, Al-Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9(6):665–71.
Article
PubMed
PubMed Central
Google Scholar
Memish ZA, Ahmed QA. Mecca bound: the challenges ahead. J Travel Med. 2002;9(4):202–10.
Article
PubMed
Google Scholar
Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36(6):679–83.
Article
PubMed
Google Scholar
Borrow R. Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis. 2009;7(4):219–25.
Article
PubMed
Google Scholar
Menomune: Package Insert. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf. [Accessed 22 January 2015].
Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–20.
Article
CAS
PubMed
Google Scholar
Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10(4):995–1007.
Article
PubMed
PubMed Central
Google Scholar
Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines. 2006;5(6):851–7.
Article
CAS
PubMed
Google Scholar
Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–43.
Article
PubMed
Google Scholar
Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–6.
Article
PubMed
PubMed Central
Google Scholar
Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181(2):761–4.
Article
CAS
PubMed
Google Scholar
Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30(3):e41–8.
Bermal N, Huang LM, Dubey AP, Jain H, Bavdekar A, Lin TY, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7(2):239–47.
Article
CAS
PubMed
Google Scholar
Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother. 2012;8(7):866–72.
Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28(3):744–53.
Article
CAS
PubMed
Google Scholar
Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29(25):4264–73.
Article
CAS
PubMed
Google Scholar
Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011;30(4):e56–62.
Article
PubMed
Google Scholar
Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine. 2009;27(1):161–8.
Article
CAS
PubMed
Google Scholar
Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine. 2011;29(25):4274–84.
Article
CAS
PubMed
Google Scholar
Findlow H, Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Adv Ther. 2013;30(5):431–58.
Article
CAS
PubMed
Google Scholar
Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13:116.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2013;17(3):e173–6.
Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years. Hum Vaccin Immunother. 2012;8(12):1882–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8(12):1892–903.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, Dimaano E, Bianco V, Baine Y, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother. 2012;8(7):873–80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vesikari T, Forsten A, Bianco V, Van Der Wielen M, Miller JM. Antibody persistence to meningococcal serogroups A, C, W and y in toddlers two years after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate (MenACWY-TT) vaccine as measured by bactericidal antibody assays using rabbit or human complement. Trials in Vaccinology. 2014;3(1):121–6.
Article
Google Scholar
Memish Z, Al Hakeem R, Al Neel O, Danis K, Jasir A, Eibach D. Laboratory-confirmed invasive meningococcal disease: effect of the Hajj vaccination policy, Saudi Arabia, 1995 to 2011. Euro Surveill. 2013;18:37.
Article
Google Scholar
Memish ZA. Health conditions for travelers to Saudi Arabia for (Hajj) for the year 1431H/2010. J Infect Public Health. 2010;3(3):92–4.
Article
PubMed
Google Scholar
World Health Organization: Global Alert and Response (GAR). Meningococcal disease. [http://www.who.int/csr/don/archive/disease/meningococcal_disease/en/].
World Health Organization: WHO vaccine-preventable diseases: monitoring system. 2013 global summary. [http://apps.who.int/immunization_monitoring/globalsummary].
Steffen R. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med. 2010;17(Suppl):9–17.
Article
PubMed
Google Scholar
Philippine Foundation for Vaccination (PFV) [http://www.philvaccine.org/vaccination-schedules/].
Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents. Hum Vaccin. 2010;6(11):881–7.
Article
PubMed
PubMed Central
Google Scholar
Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006;193(6):821–8.
Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013;32(4):e170–7.
Article
PubMed
Google Scholar
Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745–52.
Article
CAS
PubMed
Google Scholar
Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4(2):156–67.
CAS
PubMed
PubMed Central
Google Scholar
Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–7.
Article
CAS
PubMed
Google Scholar
Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69(3):1568–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Clopper CP, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–13.
Article
Google Scholar
Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine. 1998;17(8):857–72.
Article
CAS
PubMed
Google Scholar
European Centre for Disease Control and Prevention. Annual epidemiological report 2014 – Vaccine-preventable diseases – invasive bacterial diseases. Stockholm: ECDC; 2015. Accesible at: http://ecdc.europa.eu/en/publications/Publications/AER-VPD-IBD-2014.pdf
MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, et al. Social Behavior and Meningococcal Carriage in British Teenagers. Emerg Infect Dis. 2006;12(6):950–7.
Article
PubMed
PubMed Central
Google Scholar
Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61.
Article
PubMed
Google Scholar
Soriano-Gabarro M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther. 2011;9(9):761–74.
Article
PubMed
Google Scholar
Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28(2):86–91.
Article
PubMed
Google Scholar
Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907–13.
Article
PubMed
Google Scholar